C12N 2760/14133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/14133 (Use of viral protein as therapeutic agent other than vaccine) appears on 2 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 2
- Published applications
- 8
- Assignees
- 9
- Inventors
- 24
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof18 Sep 2025US 2025/0288658 A1Dana-Farber Cancer Institute, Inc.
- Self-amplifying messenger rna12 Sep 2024US 2024/0301006 A1Glaxosmithkline Biologicals SA
- Antiviral structurally-stabilized ebolavirus peptides and uses thereof4 Jan 2024US 2024/0002450 A1Dana-Farber Cancer Institute, Inc.
- Lipid-peptide fusion inhibitors as sars-cov-2 antivirals25 May 2023US 2023/0159597 A1Wisconsin Alumni Research Foundation
- Ebolavirus pre-hairpin intermediate mimics and methods of use31 Aug 2017US 2017/0247418 A1Navigen, Inc.
Most cited
By later US patents